AR and neoplasm: Given these growth factors and tumour-promoting cytokines are enriched in the tumour microenvironment, it is reasonable to believe that AR target therapy provides an opportunity for NTD to mediate ligand-independent AR signalling through crosstalk with intracellular kinases to confer tumours therapy resistance.